Conmed Corporation

Valuation Analysis

About the Company

Conmed Corporation en bref

Conmed Corporation (CNMD) is currently trading at 28,40 € with a market capitalization of 855 M €. The trailing P/E ratio stands at 18.41x, with a forward P/E of 6.8x. The 52-week range spans from 27,76 € to 49,38 €; the current price is 42.5% below the yearly high. Year-over-year revenue growth stands at -1.3%. The net profit margin stands at 4%.

💰 Dividende

Conmed Corporation pays an annual dividend of 0,70 € per share, representing a yield of 2.46%. The payout ratio stands at 22.6%.

📊 Avis des analystes

5 analystes évaluent Conmed Corporation (CNMD) au consensus : Conserver. L'objectif de cours moyen est de 34,52 €, soit un potentiel de +21.55% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 34,00 € à 34,87 €.

Conmed Corporation : la thèse d'investissement en détail

Conmed Corporation (CNMD) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 136.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

Le scénario baissier

Revenue is contracting at -1.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. With a net margin of just 4%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

Valorisation en contexte

The EV/EBITDA multiple of 8.86x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 6.8x is meaningfully below the trailing 18.41x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 21.55% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.24%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Conmed Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.